Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

OBJECTIVE: Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol. METHODS: During t...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatt, Sophie, Taylor, Peter C, McInnes, Iain B, Schett, Georg, Landewé, Robert, Baeten, Dominique, Ionescu, Lucian, Strimenopoulou, Foteini, Watling, Mark I L, Shaw, Stevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691864/
https://www.ncbi.nlm.nih.gov/pubmed/31177099
http://dx.doi.org/10.1136/annrheumdis-2018-214943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691864/
https://www.ncbi.nlm.nih.gov/pubmed/31177099
http://dx.doi.org/10.1136/annrheumdis-2018-214943

Ejemplares similares